United Therapeutics Co. (NASDAQ:UTHR – Get Rating)’s stock price traded down 3.1% during mid-day trading on Thursday following insider selling activity. The company traded as low as $224.15 and last traded at $224.15. 401 shares were traded during trading, a decline of 100% from the average session volume of 571,206 shares. The stock had previously closed at $231.29.Specifically, CEO Martine A. Rothblatt sold 3,000 shares of the stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $231.27, for a total value of $693,810.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,065.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $182.42, for a total transaction of $1,094,520.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,000 shares of company stock valued at $9,390,830. 12.10% of the stock is currently owned by insiders.